Wells Fargo’s Cytek Biosciences CTKB Stock Holding History
Bought
Maintained
Sold
Other funds holding CTKB
Wells Fargo's CTKB Position: Q3 2026 in Review
Wells Fargo reduced its Cytek Biosciences (CTKB) stake by 76% in Q3 2026, selling an estimated $371K and leaving 24,530 shares worth $146K. The position accounts for ﹤0.01% of the portfolio, ranked #4901.
Wells Fargo first reported a position in CTKB in Q3 2021 and has held it in 21 quarters since. The position peaked at $670K in Q4 2025. 150 funds tracked by Wall St. Rank hold CTKB as of Q3 2026.
- Wells Fargo held 24,530 shares of Cytek Biosciences worth $146K as of Q3 2026.
- Wells Fargo sold 78,174 Cytek Biosciences shares in Q3 2026, an estimated $371K.
- Cytek Biosciences made up ﹤0.01% of Wells Fargo's portfolio in Q3 2026, its #4901 holding.
- Wells Fargo first reported a position in Cytek Biosciences in Q3 2021 and has held it in 21 quarters since.
- Wells Fargo's Cytek Biosciences position peaked at $670K in Q4 2025.
- 150 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2026.
Based on Wells Fargo's 13F filing for Q3 2026, filed 16 Nov 2026.